23andMe Investor Presentation Deck

Patients + Caregivers DESPERATELY seeking survival Targeted therapy Standard therapy Survival- 1 2 CD200R1 Basal cell carcinoma H Hypothyroidism Hashimoto's 30 Years after diagnosis CD200 CD200/R1 is a dominant immune checkpoint* Basal cell carcinoma Any allergy '610 Development Rationale Addressing Critical Unmet Need in Solid Tumors Allergic Asthma Juvenile Asthma Any asthma 1 DOK2 Immunotherapy Standard therapy Basal cell carcinoma Mosquito bite Itcn/size Eczema 2 Any asthma Any allergy Juvenile asthma Any animal allergy ©nature 10 Cancer Immune 10 5 Y 2 -5 3 -10 -Log(P value) CD200K (inhibitory cell surface receptor), CD200 (CD200R1 ligand), and DOK2 (involved in the CD200/CD200R1 signaling pathway). *PMIDS: 12960329, 23602662, 22264927, 19786546, 15557172, 22491458, 15220441, 34326171, 18081533, 24388216, 11099416 Potential activity in >60% of current patients not deriving efficacy from PD-(L)1 inhibitors Average Percent Change CD200 . Mean EASI Percent Change from Baseline by Treatment in Atopic Dermatitis* Targeted by samalizumab for CLL and MM, failed to achieve target saturation" Highly expressed on tumor, stromal, and endothelial cells 8 12 Week A Last dose Follow-up Period 16 20 24 CD200R1 ●CD200R Placebo Restricted immune expression: myeloid > T > B 23ME-00610 ('610) is first-in-class Lilly's Ucenprubart: Clinical POC for CD200/R1 agonism in immune disease *PMID: 31443741; https://investor.lilly.com/static-files/9efbede9-bd6a-4d7b-823e-2996b1c2d114 Copyright © 2024 23and Me, Inc. 23andMe 23

View entire presentation